ClearPoint Neuro (CLPT) Q2 2026: Earnings Miss as Cash Burns Faster
As seen on the 24/7 Wall St. homepage on August 3, 2026.
ClearPoint Neuro's pivot toward drug delivery readiness ahead of 2027 partner approvals now runs on a tighter clock: cash fell to $29.4 million from $45.9 million at the start of the year. The company also cut full-year 2026 revenue guidance to $48 million to $52 million and missed expectations on both lines as the IRRAS integration lifted operating expenses.
Continue ReadingShow less
ClearPoint Neuro reported a Q2 2026 loss of $0.38 per share, coming in about 33% worse than the consensus estimate of roughly $0.29. Revenue of $10.88 million also fell short, trailing expectations of $12.73 million by more than 14%. The IRRAS integration was cited as a driver of higher operating expenses, squeezing results on both lines simultaneously.
The cash picture adds urgency to the story. The company's cash position dropped to $29.4 million from $45.9 million at the start of 2026, a meaningful drawdown in just two quarters. That tighter runway matters because ClearPoint is positioning itself around drug delivery readiness ahead of partner approval milestones it is targeting for 2027, leaving limited room for further cost overruns.
Sponsored
Don't wait: the analyst who called NVIDIA in 2010 just revealed his top 10 AI stocks. See the full list FREE now.
The company also trimmed its full-year 2026 revenue guidance to a range of $48 million to $52 million. Looking back at recent EPS history, losses have widened steadily — from $0.21 in Q2 2025 to $0.27 in Q4 2025, $0.32 in Q1 2026, and now $0.38 — and the reported figure has consistently come in worse than estimates over that stretch, suggesting consensus has had difficulty keeping pace with the cost trajectory.
Mentioned: CLPT